AstraZeneca awarded damages in Prilosec® patent litigation
4 December 2013 | By AstraZeneca
AstraZeneca announced a ruling by the US District Court for the Southern District of New York which ordered Apotex Corp., Apotex, Inc and Torpharm, Inc...
List view / Grid view
News
New data at American Society of Hematology (ASH) Annuaul Meeting will offer important insights into safe and efficacious use of XARELTO®
3 December 2013 | By
XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today...
Sareum Enters Co-Development Agreement in China for Aurora+FLT3 Programme
3 December 2013 | By Sareum Holdings plc
Sareum Holdings plc is pleased to announce that it has signed a co-development agreement with Hebei Medical University Biomedical Engineering Center to advance its Aurora+FLT3 cancer programme...
Lundbeck appoints Senior Vice President for Business Development and HR
3 December 2013 | By Lundbeck
Jacob Tolstrup, Lundbeck's Vice President for Business Development, will now also be in charge of the company's HR department. The Vice President for HR, Teddy Hebo Larsen, has resigned at his own request...
Sanofi announces new phase 3 results for investigational new insulin U300
3 December 2013 | By Sanofi
EDITION II trial demonstrates similar blood sugar control with fewer night-time low blood sugar events for U300 compared with Lantus®...
Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes
3 December 2013 | By Boehringer Ingelheim
Boehringer Ingelheim (BI) and Eli Lilly and Company today announced new data1 from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes (T2D).
Biogen Idec receives notification from FDA of PDUFA date extension for ALPROLIX™
2 December 2013 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has extended the initial Prescription Drug User Fee Act date for its review of the Biologics License Application for ALPROLIX...
Largest global survey investigating early type 2 diabetes conversations launched by Boehringer Ingelheim and Eli Lilly and Company in partnership with the International Diabetes Federation
2 December 2013 | By Boehringer Ingelheim
The survey was developed in partnership with the International Diabetes Federation (IDF) and will include more than 10,000 people with T2D and more than 6,500 treating-physicians...
Novartis Foundation launches new leprosy strategy at symposium on disease elimination
29 November 2013 | By Novartis
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria...
Daiichi Sankyo launches natural tetrahydrobiopterin agent Biopten® Granules 10%
29 November 2013 | By Daiichi Sankyo Company,
Biopten is a highly pure, chemically synthesized form of natural tetrahydrobiopterin (hereafter, BH4) that occurs naturally in the human body...
New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
GSK receives positive CHMP opinion for Cervarix™ two-dose schedule
28 November 2013 | By GlaxoSmithKline
GSK announced that the European Medicines Agency's Committee for Medicinal Products for Human Use is recommending marketing authorisation for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix™...
Mettler-Toledo to present live webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing”
27 November 2013 | By Mettler Toledo
Mettler-Toledo announced an upcoming webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing" with special guest presenter Mr. Gregory Martin, President of Complectors Consulting LLC...
